CTLA4 and melanoma: Then, we calculated the numTS values for the selected miRNAs using the RNA-Seq data of 105 advanced melanoma samples collected from patients before and after nivolumab (anti-PD-1 agent) and ipilimumab (anti-CTLA-4) administration (pre- and post-treatment, respectively) (25).